Skip to main content
S&P 5007,811.54+0.59%DOW51,654.95+0.83%NASDAQ27,366.17+0.64%BTC$83,249.00+0.29%ETH$2,539.68+1.50%GOLD$4,196.20-0.48%OIL$92.98+1.23%
Smart Investors Daily
SID Premium
VC

NASDAQ · VCYT

Veracyte, Inc.

Healthcare · Biotechnology

$45.23

Up+$1.63 (+3.74%)

Updated Oct 12, 2026, 11:51 AM

SID Score

5.7/10

Composite research score

Smart Money

58/100

Neutral

Market cap
3.34B
P/E ratio
109.61
Dividend yield
0.00%
52-week range
$29.46 – $60.91
Volume
966.61K
Avg. volume
966.7K

Price performance · VCYT

VCYT price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 9, 2026

VCYT closed at $45.23 after 20 trading sessions, up 9.75% for the selected period.

Last close
$45.23
Period change
+9.75%
Period low
$38.50
Period high
$48.54
Daily close
View OHLC price history
VCYT OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 9, 2026$43.705$46.17$43.50$45.23966.61K
Oct 8, 2026$42.50$43.67$41.215$43.601.22M
Oct 7, 2026$44.04$44.21$42.34$43.161.21M
Oct 6, 2026$48.00$48.84$44.0872$44.651.73M
Oct 5, 2026$45.75$47.785$45.00$47.671.29M
Oct 2, 2026$44.94$46.09$44.41$45.811.04M
Oct 1, 2026$45.66$47.14$44.18$44.191.43M
Sep 30, 2026$45.93$46.78$45.60$46.041.18M
Sep 29, 2026$46.00$47.52$45.21$46.081.59M
Sep 28, 2026$45.04$47.52$44.47$45.231.7M
Sep 25, 2026$49.00$49.00$45.36$45.431.73M
Sep 24, 2026$43.66$48.95$43.51$48.542.88M
Sep 23, 2026$42.95$43.86$42.25$43.821.53M
Sep 22, 2026$41.76$43.74$41.3151$43.361.47M
Sep 21, 2026$40.00$41.9789$39.395$41.521.47M
Sep 18, 2026$40.41$41.05$39.55$39.7952.67M
Sep 17, 2026$39.67$40.70$38.80$40.571.47M
Sep 16, 2026$40.36$41.45$38.245$38.501.62M
Sep 15, 2026$40.83$42.36$39.095$40.141.76M
Sep 14, 2026$41.17$41.403$40.50$41.211.03M

Latest VCYT news

The latest Smart Investors Daily articles mentioning VCYT.

Stock researchCompany · Overview

VCYT research

Overview

Company profile and research snapshot.

Company profile

Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$46.33
Implied upside
—
Analysts
—
VCYT recent ratings
DateFirmRatingTarget
Sep 15, 2026Freedom Capital MarketsBuy—
Sep 9, 2026UBSBuy—
Aug 4, 2026Piper SandlerOverweight—
Aug 4, 2026Stephens & Co.Overweight—
Aug 4, 2026Morgan StanleyUnderweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 2, 2026

Veracyte (VCYT) Could Be 22% Undervalued After New Decipher Phase III Data

Veracyte (VCYT) is back in focus after new phase III data on its Decipher Prostate Genomic Classifier showed it can help identify which intermediate-risk prostate cancer patients benefit most from adding short-term hormone therapy. Investors have seen momentum cool in recent weeks, with Veracyte’s share price falling 4.0% on the day and 9.0% over the past week, while the 90 day share price return is down 22.6%. Yet the 1 year total shareholder return of 24.0% and 3 year total shareholder...

Yahoo · Oct 2, 2026

Veracyte (VCYT) Is Down 9.0% After New Level 1B1 Decipher Prostate Data at ASTRO 2026

Veracyte, Inc. recently presented retrospective ancillary Phase III NRG/RTOG 0815 trial data at the 2026 ASTRO meeting, showing that its Decipher Prostate Genomic Classifier can stratify which intermediate-risk prostate cancer patients benefit from adding short-term androgen deprivation therapy to dose-escalated radiation, with Level 1B1 prognostic and predictive evidence. The findings suggest Decipher could help physicians better balance treatment benefit against the metabolic and...

Yahoo · Oct 1, 2026

Could Veracyte (VCYT) Change Prostate Cancer Care With New Phase III Data?

Veracyte (NasdaqGM:VCYT) reported new phase III data showing its Decipher Prostate Genomic Classifier can guide hormone therapy use with radiation in intermediate-risk prostate cancer. The phase III trial provided prospective evidence that Decipher can help identify which patients are more likely to benefit from adding hormone therapy to radiation treatment. Findings suggest Decipher may extend its role from prognosis to predicting treatment benefit, potentially influencing how clinicians...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By